Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study.
| Title: | Effectiveness and Tolerability of Trimetazidine 80 mg Once Daily in Patients with Chronic Coronary Syndrome in Brazil: The V-GOOD Observational Study. |
|---|---|
| Authors: | Gowdak LHW; Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research Organization, São Paulo, Brazil. luis.gowdak@incor.usp.br.; Atherosclerosis and Chronic Coronary Artery Disease Unit-Heart Institute, Av Dr Eneas de Carvalho Aguiar, 44-2nd Floor, Building 2, São Paulo, SP, 05403-000, Brazil. luis.gowdak@incor.usp.br.; Dourado PMM; Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Unidade de Hipertensão Experimental, São Paulo, Brazil.; Précoma DB; Hospital Angelina Caronl, Curitiba, Brazil.; de Oliviera Lopes Dusilek C; Hospital do Rocio, Núcleo de Pesquisa Clínica, Campo Largo, Brazil.; da Silva FM; Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.; Yugar-Toledo JC; Instituto de Cardiologia e Endocrinologia São José do Rio Preto, São José do Rio Preto, Brazil.; Pena FM; Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.; de Almeida Gomes DA; Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research Organization, São Paulo, Brazil.; do Espírito Santo Cestário E; Centro Universitário de Votuporanga, Votuporanga, Brazil.; Guimarães OR Jr; Santa Casa de Alfenas, Alfenas, Brazil.; Filho CRH; Centro Multidisciplinar de Ensino Especializado e Pesquisa, Joinville, Brazil.; de Almeida CF; Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Academic Research Organization, São Paulo, Brazil.; de Souza Brito F; Indacor, Centro de Pesquisa, Indaiatuba, Brazil.; Martins GF; Instituto Estadual de Cardiologia Aloysio de Castro, Rio de Janeiro, Brazil.; Ferreira VRR; Braile Cardio, São José do Rio Preto, Brazil.; Flores MC; Laboratório Servier do Brasil, Rio de Janeiro, RJ, Brazil.; da Silva ML; Laboratório Servier do Brasil, Rio de Janeiro, RJ, Brazil. |
| Corporate Authors: | V-GOOD Investigators |
| Source: | Cardiology and therapy [Cardiol Ther] 2025 Jun; Vol. 14 (2), pp. 249-265. Date of Electronic Publication: 2025 Apr 29. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer Healthcare Country of Publication: England NLM ID: 101634495 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8261 (Print) Linking ISSN: 21936544 NLM ISO Abbreviation: Cardiol Ther Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [London] : Springer Healthcare |
| Abstract: | Introduction: The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice.; Methods: This prospective, observational study involved 1026 adult outpatients with symptomatic CCS from 70 sites in Brazil who were prescribed trimetazidine MR 80 mg OD plus background antianginal treatment. Data on number of angina attacks, short-acting nitrate consumption, prevalence of angina-free patients, severity of angina, patient-reported daily physical activity impairment, treatment adherence, tolerability, and cardiologist and patient satisfaction were collected at baseline (V1), then at 1 month (V2) and 3 months (V3).; Results: Following the addition of trimetazidine MR 80 mg OD, the mean ± standard deviation number of angina attacks per week decreased from 3.1 ± 2.8 at V1 to 1.0 ± 2.1 at V2, and 0.7 ± 1.7 at V3, with concurrent reductions in short-acting nitrate consumption, patient-reported daily physical activity impairment and the proportion of patients with limiting angina (Canadian Cardiovascular Society class III or IV), and increases in the proportion of angina-free patients (all p |
| Competing Interests: | Declarations. Conflict of Interest: Luís Henrique Wolff Gowdak has received payments or honoraria from Servier and Novartis, support for attending meetings and/or travel from Servier, and has served on a data safety monitoring board and advisory board for Servier. Elizabeth do Espírito Santo Cestário has received payments for lectures given at events sponsored by Laboratório Servier do Brasil. Paulo Magno Martins Dourado, Dalton Bertolim Précoma, César de Oliviera Lopes Dusilek, Francisco Maia da Silva, Juan Carlos Yugar-Toledo, Felipe Montes Pena, Domingos Antônio de Almeida Gomes, Olavo Raimundo Guimarães Jr, Conrado Roberto Hoffmann Filho, Carlos Filinto de Almeida, Flávio de Souza Brito, Gerez Fernandes Martins, and Victor Rodrigues Ribeiro Ferreira declare no potential competing interests. Marcella Chaves Flores and Mayara Lídia da Silva are currently employed by Servier Brazil. Ethical Approval: The study was performed in accordance with good clinical practice and the ethical principles derived from the revised Declaration of Helsinki. The Institutional Review Board of the National Coordinator Centre (Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil [4.884.990, approved on August 4, 2021]) approved the study protocol before the start of the study. The STROBE guidelines were used in reporting this study [25]. Participants provided written informed consent prior to their enrollment in the study. |
| References: | Cardiol Rev. 2007 Sep-Oct;15(5):257-63. (PMID: 17700384); Am Heart J. 2003 Nov;146(5):E18. (PMID: 14597947); Front Pharmacol. 2012 Nov 06;3:191. (PMID: 23133420); Lancet. 2022 Feb 12;399(10325):691-694. (PMID: 35033221); Cardiology. 2011;120(2):59-72. (PMID: 22122948); Br J Clin Pharmacol. 1994 Mar;37(3):279-88. (PMID: 8198938); J Clin Epidemiol. 2008 Apr;61(4):344-9. (PMID: 18313558); Curr Probl Cardiol. 2023 Jan;48(1):101420. (PMID: 36183980); Eur Heart J. 2019 Aug 1;40(29):2455-2462. (PMID: 30608528); Circulation. 2023 Aug 29;148(9):e9-e119. (PMID: 37471501); Arch Mal Coeur Vaiss. 2001 Aug;94(8):839-42. (PMID: 11575214); Eur Heart J. 2020 Jan 14;41(3):347-356. (PMID: 31504434); Int J Cardiol. 2019 Oct 15;293:39-44. (PMID: 31178223); Int J Cardiol. 2016 Jan 15;203:909-15. (PMID: 26618252); Angiology. 2019 May;70(5):397-406. (PMID: 30149731); Arq Bras Cardiol. 2022 Jan;118(1):115-373. (PMID: 35195219); Circulation. 2021 Aug 17;144(7):512-523. (PMID: 34261331); Arq Bras Cardiol. 2014 Aug;103(2 Suppl 2):1-56. (PMID: 25410086); J Am Coll Cardiol. 2012 Sep 11;60(11):951-6. (PMID: 22954239); Am J Ther. 2005 Jan-Feb;12(1):35-42. (PMID: 15662290); Adv Ther. 2018 Sep;35(9):1368-1377. (PMID: 30105656); Chest. 2014 Jul;146(1):73-80. (PMID: 24811214); Nat Rev Cardiol. 2018 Feb;15(2):120-132. (PMID: 28880025); PLoS One. 2022 Feb 11;17(2):e0263932. (PMID: 35148340); Eur Heart J. 2001 Dec;22(24):2267-74. (PMID: 11728147); Cardiol Ther. 2022 Mar;11(1):93-111. (PMID: 34958427); Arch Intern Med. 2009 Sep 14;169(16):1491-9. (PMID: 19752407); Cardiol Ther. 2018 Jun;7(1):61-70. (PMID: 29779201); Int J Cardiol. 2014 Dec 20;177(3):780-5. (PMID: 25466565); Hypertension. 2019 May;73(5):e35-e66. (PMID: 30827125); Eur Heart J. 2024 Sep 29;45(36):3415-3537. (PMID: 39210710); Lancet. 2018 Jan 6;391(10115):31-40. (PMID: 29103656); J Am Coll Cardiol. 2023 Feb 7;81(5):505-514. (PMID: 36725179); Int J Cardiol. 2016 Aug 1;216:104-9. (PMID: 27144286) |
| Contributed Indexing: | Keywords: Angina pectoris; Chronic coronary syndrome; Stable angina; Trimetazidine |
| Molecular Sequence: | ClinicalTrials.gov NCT06464276 |
| Entry Date(s): | Date Created: 20250429 Latest Revision: 20250519 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12084445 |
| DOI: | 10.1007/s40119-025-00405-9 |
| PMID: | 40299195 |
| Database: | MEDLINE |
Journal Article